A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

Summary

This is a randomized, open-label, multicenter Phase II clinical trial evaluating the efficacy and safety of HB1801 compared with Taxotere® in patients with advanced breast cancer. A total of 60 subjects with advanced breast cancer are planned to be enrolled.The trial consists of three phases: screening period, open-label treatment period, and follow-up period. HB1801 is Docetaxel for injection (Albumin-bound).

Timeline

Start

2025-08-15

Primary completion

2026-10-11

Completion

2026-12-31

Drugs

Indications